Home PI3K/Akt/mTOR PIKfyve

PIKfyve Inhibitors

PIKfyve Products

  • All (5)
  • PIKfyve Inhibitors (5)
  • New PIKfyve Products
Cat.No. Product Name Information Product Use Citations Product Validations
S1219 YM201636 YM201636 is a selective PIKfyve inhibitor with IC50 of 33 nM, less potent to p110α and insensitive to Fabl (yeast orthologue). This compound suppresses the growth of liver cancer via the induction of autophagy.
Mol Biol Cell, 2024, 35(5):ar70
Nat Commun, 2022, 13(1):2136
Blood Cancer J, 2022, 12(3):39
Verified customer review of YM201636
S6414 Apilimod Apilimod is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. This compound inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. It is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM.
Nat Commun, 2025, 16(1):8123
J Cell Biol, 2025, 224(6)e202408158
J Biol Chem, 2025, 301(10):110716
S6912 Vacuolin-1 Vacuolin-1 is a potent and cell-permeable inhibitor that blocks the Ca(2+)-dependent exocytosis of lysosomes and prevents the release of lysosomal content without affecting the process of resealing. This compound is also a potent and selective PIKfyve inhibitor, and inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition.
Autophagy, 2025, 1-15.
Virulence, 2024, 15(1):2350893
Virulence, 2024, 15(1):2350893
S0785 Apilimod mesylate Apilimod mesylate is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. This compound inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. It is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM.
bioRxiv, 2024, 2024.02.28.582543
Stem Cell Reports, 2022, 17(2):397-412
Hum Mol Genet, 2021, 29(22):3589-3605
E2933 MOMIPP MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. This compound readily penetrates the blood-brain barrier and is moderately effective in suppressing progression of intracerebral glioblastoma xenografts.
S1219 YM201636 YM201636 is a selective PIKfyve inhibitor with IC50 of 33 nM, less potent to p110α and insensitive to Fabl (yeast orthologue). This compound suppresses the growth of liver cancer via the induction of autophagy.
Mol Biol Cell, 2024, 35(5):ar70
Nat Commun, 2022, 13(1):2136
Blood Cancer J, 2022, 12(3):39
 Verified customer review of YM201636
S6414 Apilimod Apilimod is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. This compound inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. It is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM.
Nat Commun, 2025, 16(1):8123
J Cell Biol, 2025, 224(6)e202408158
J Biol Chem, 2025, 301(10):110716
S6912 Vacuolin-1 Vacuolin-1 is a potent and cell-permeable inhibitor that blocks the Ca(2+)-dependent exocytosis of lysosomes and prevents the release of lysosomal content without affecting the process of resealing. This compound is also a potent and selective PIKfyve inhibitor, and inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition.
Autophagy, 2025, 1-15.
Virulence, 2024, 15(1):2350893
Virulence, 2024, 15(1):2350893
S0785 Apilimod mesylate Apilimod mesylate is a potent and orally-available inhibitor of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23) with the potential to treat certain autoimmune and inflammatory diseases. This compound inhibits IL-12 with IC50 of 1 nM, 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs, human monocytes and mouse PBMCs, respectively. It is also a cell permeable small molecule that specifically inhibits PIKfyve with IC50 of 14 nM.
bioRxiv, 2024, 2024.02.28.582543
Stem Cell Reports, 2022, 17(2):397-412
Hum Mol Genet, 2021, 29(22):3589-3605
E2933 MOMIPP MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. This compound readily penetrates the blood-brain barrier and is moderately effective in suppressing progression of intracerebral glioblastoma xenografts.